Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Nitrazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 4/20 | 0.59 |
| ▸ | GABRG2 known ✓ | P18507 | 4/20 | 0.59 |
| ▸ | GABRB3 known ✓ | P28472 | 4/20 | 0.59 |
| ▸ | GABRA5 known ✓ | P31644 | 4/20 | 0.59 |
| ▸ | GABRA3 known ✓ | P34903 | 4/20 | 0.59 |
| ▸ | GABRA2 known ✓ | P47869 | 4/20 | 0.59 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 0.59 |
| ▸ | GABRP known ✓ | O00591 | 3/20 | 0.59 |
| ▸ | GABRD known ✓ | O14764 | 3/20 | 0.59 |
| ▸ | GABRB1 known ✓ | P18505 | 3/20 | 0.59 |
| ▸ | GABRA4 known ✓ | P48169 | 3/20 | 0.59 |
| ▸ | GABRE known ✓ | P78334 | 3/20 | 0.59 |
| ▸ | GABRA6 known ✓ | Q16445 | 3/20 | 0.59 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 3/20 | 0.59 |
| ▸ | GABRG3 known ✓ | Q99928 | 3/20 | 0.59 |
| ▸ | GABRQ known ✓ | Q9UN88 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxazepam SCHEMBL6680438 | 0.91 | LMNA (0.81) | LMNAPDE4DHPGDMEN1KMT2A | |
| Clonazepam SCHEMBL5500649 | 0.89 | GABRA1 (0.74) | LMNAPDE4DHPGDMEN1KMT2A | |
| SCHEMBL11394894 | 0.86 | LMNA (0.67) | LMNAPDE4DHPGDMEN1KMT2A | |
| Delorazepam SCHEMBL6130036 | 0.84 | LMNA (0.73) | LMNAPDE4DMEN1KMT2AALB | |
| Clonazepam SCHEMBL16719271 | 0.84 | GABRA1 (0.61) | LMNAPDE4DHPGDMEN1KMT2A | |
| Nitrazepam SCHEMBL9747297 | 0.84 | PDE4D (1.00) | LMNAPDE4DHPGDMEN1KMT2A | |
| Nitrazepam SCHEMBL35202 | 0.84 | PDE4D (1.00) | LMNAPDE4DHPGDMEN1KMT2A | |
| Nitrazepam SCHEMBL29408437 | 0.84 | PDE4D (1.00) | LMNAPDE4DHPGDMEN1KMT2A | |
| SCHEMBL7721819 | 0.82 | LMNA (0.78) | LMNAPDE4DHPGDMEN1KMT2A | |
| Oxazepam SCHEMBL5498881 | 0.82 | LMNA (1.00) | LMNAPDE4DMEN1KMT2AALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090304801-A1 | AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE | ELAN PHARMA INTERNATIONAL LIMITED | 2009-12-10 | — | — | US | claimed |
| US-20230405025-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND USE FOR TREATING AND PREVENTING DISEASES | Max Biology Co. Ltd. (KH) | 2023-12-21 | — | — | US | disclosed |
| EP-4225298-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND USE FOR TREATING AND PREVENTING DISEASES | MAX BIOLOGY CO. LTD. (KH) | 2023-08-16 | — | — | EP | disclosed |
| EP-2353590-A1 | Aerosol and injectable formulations of nanoparticulate benzodiazepine | Elan Pharma International Limited (IE) | 2011-08-10 | — | — | EP | disclosed |
| EP-2332524-A1 | Aerosol and injectable formulations of nanoparticulate benzodiazepine | Elan Pharma International Limited (IE) | 2011-06-15 | — | — | EP | disclosed |
| US-20090304801-A1 | AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE | ELAN PHARMA INTERNATIONAL LIMITED | 2009-12-10 | — | — | US | disclosed |
| EP-1853234-A2 | AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE | Elan Pharma International Limited (IE) | 2007-11-14 | — | — | EP | disclosed |
| US-20060198896-A1 | Aerosol and injectable formulations of nanoparticulate benzodiazepine | ELAN PHARMA INTERNATIONAL LIMITED | 2006-09-07 | — | — | US | disclosed |
| WO-2006088894-A2 | AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060198896-A1 | Aerosol and injectable formulations of nanoparticulate benzodiazepine | GABRA1, GABRA4, GABRA6 | GABRA1 1/4885GABRG2 11/4885GABRB3 13/4885 |
| US-20230405025-A1 | CANNABINOID-CONTAINING COMPOSITIONS AND USE FOR TREATING AND PREVENTING DISEASES | CNR2, CNR1, FAAH | GABRA1 1329/4885GABRG2 1223/4885GABRB3 1936/4885 |
| US-20090304801-A1 | AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE | GABRA1, GABRA4, GABRA6 | GABRA1 1/4885GABRG2 11/4885GABRB3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.